Get the Stockscreener App
0.3401
10.35%
0.0319
After Hours:
.34
-0.000100
-0.03%
Renovaro Inc stock is traded at $0.3401, with a volume of 1.03M.
It is up +10.35% in the last 24 hours and down -7.63% over the past month.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
See More
Previous Close:
$0.3082
Open:
$0.3251
24h Volume:
1.03M
Relative Volume:
0.31
Market Cap:
$58.54M
Revenue:
-
Net Income/Loss:
$-41.23M
P/E Ratio:
-0.4859
EPS:
-0.7
Net Cash Flow:
$-11.54M
1W Performance:
+0.32%
1M Performance:
-7.63%
6M Performance:
-67.30%
1Y Performance:
-74.43%
1-Day Range:
$0.3251
$0.348
1-Week Range:
$0.3013
$0.36
52-Week Range:
$0.264
$2.10
Renovaro Inc Stock (RENB) Company Profile
Name
Renovaro Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare RENB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RENB
Renovaro Inc
|
0.3401 | 69.57M | 0 | -41.23M | -11.54M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovaro Inc Stock (RENB) Latest News
Renovaro Inc. Stock Analysis and ForecastHigh-profit capital plays - Autocar Professional
What analysts say about Renovaro Inc. stockRapidly growing investment returns - Autocar Professional
What drives Renovaro Inc. stock priceFree Stock Movement Tracking - jammulinksnews.com
Is Renovaro Inc. a good long term investmentRapid wealth accumulation - jammulinksnews.com
Can Renovaro Inc. stock recover from recent declineDaily Breakout Picks - Newser
What makes Renovaro Inc. stock price move sharplySmart Return Focused Trading - Newser
Renovaro Biosciences (RENB) Achieves Milestone with Innovative C - GuruFocus
Revolutionary Dendritic Cell Therapy Slashes Pancreatic Cancer Tumors by 81% in Groundbreaking Study - Stock Titan
Renovaro Inc (RENB) Stock: A Comprehensive 52-Week Review - investchronicle.com
How did Renovaro's expenses impact profits in Q2 2025? - AInvest
Renovaro Rockets 20% Higher on Legal Drama—Biotech's High-Stakes Merger Showdown - AInvest
Why Renovaro Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser
How Renovaro Inc. stock performs during market volatilityFree Consultation - Newser
Renovaro receives Nasdaq notice for missing annual shareholder meeting - Investing.com Australia
Renovaro receives Nasdaq notice for missing annual shareholder meeting By Investing.com - Investing.com Nigeria
Renovaro Biosciences Receives Nasdaq Compliance Notice - TipRanks
Renovaro BioSciences strengthens balance sheet through debt conversion - TipRanks
AI Healthcare Pioneer Renovaro Eliminates $9.7M Debt Through Strategic Conversion to Power Growth - Stock Titan
Renovaro Biosciences Restructures Debt with Exchange Agreement - TipRanks
Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives - The Globe and Mail
Predictive Oncology enters into $10M share purchase agreement with New Jersey-based firm - The Business Journals
Renovaro (NASDAQ:RENB) Shares Down 1.3% – Time to Sell? - Defense World
Renovaro Stock Soars 12.63% on Innovation, Partnerships - AInvest
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative - GuruFocus
Renovaro Inc (RENB Stock: A Sea of Opportunity - investchronicle.com
Renovaro Inc Stock (RENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):